Company Profile For Intercell AG

Intercell AG is an Austria-based company engaged in biotechnology, which focuses on the design and development of vaccines for the prevention and treatment of infectious diseases. Its antigens and adjuvant are derived from its core technologies, including the adjuvant IC31 and the Antigen Identification Program (AIP). Its core product is a Japanese Encephalitis vaccine, approved in the United States, Europe and Australia. The Company's development pipeline includes a Pseudomonas vaccine in Phase II, a Hepatitis C virus vaccine in Phase II, vaccines for Staphylococcus aureus in Phase II and Tuberculosis vaccine in Phase II, and a broad pipeline of vaccine and antibody candidates focused on infectious diseases in pre-clinical development. Intercell AG operates in Austria and it also has manufacturing facility in Scotland and research and development facility in the United States. It also has partnerships with Merck & Co, Inc, Sanofi Pasteur and Kyowa Hakko Kirin, among others.

BRIEF: For the nine months ended 30 September 2009, Intercell AG's total revenue increased 17% to EUR29.5M. Net loss for the period increased 88% to EUR25.9M. Total revenue reflects an increase in demand for the Company's products and services. Higher net loss for the period reflects higher research and development expenses and general administrative expenses as well as a decrease in financial income.

Intercell AG
Campus Vienna Biocenter 2
Vienna     1030
P: +431.206200
F: +431.20620800

403